New therapeutic options in migraine treatment
DOI:
https://doi.org/10.12775/JEHS.2024.56.002Keywords
migraine, ditans, gepants, migraine treatmentAbstract
Introduction and purpose
Migraine is a common disease mostly affecting women. It has a huge influence on patients’ life strongly decreasing its quality by cause of repetitive headache episodes and often comes with unpleasant and burdensome symptoms like photophobia, nausea or vomiting. This article focuses on migraine treatment, especially on new drugs. Primary drugs used in migraine attacks are non-steroid anti-inflammatory drugs (NSAI) and triptans. Because of their side effects and impact on internal organs, these substances are often contraindicated or inefficient. The same applies to triptans, which cannot be used by patients with cardiovascular diseases. Due to the need of a new migraine treatment path development, new remedies have been found, bringing hope for patients who could not use prior options. They are divided into two groups: ditans (lasmiditan), which are 5-HT1F serotonin receptor agonists and gepants (ubrogepant, rimegepant, atogepant and zavegepant), which are CGRP receptor antagonists. A summary of the current state of knowledge is intended to increase the awareness of physicians and patients when selecting the appropriate treatment.
Material and methods
The following review was based on articles obtained from the PubMed and Google Scholar databases. Key search terms included migraine, ditans, gepants, migraine treatment.
Conclusions
Drugs described in this study clearly show the new pathway of migraine treatment and prevention. They are safer and show more benefits than substances currently used. They can also be used in wider range of patients with conditions marked as contraindications for current schemes. However more research is still needed to fully describe their characteristics.
References
Szkutnik-Fiedler D. Pharmacokinetics, Pharmacodynamics and Drug–Drug Interactions of New Anti-Migraine Drugs—Lasmiditan, Gepants, and Calcitonin-Gene-Related Peptide (CGRP) Receptor Monoclonal Antibodies. Pharmaceutics 2020, Vol 12, Page 1180 [Internet]. 2020 Dec 3 [cited 2023 Nov 23];12(12):1180. Available from: https://www.mdpi.com/1999-4923/12/12/1180/htm
Zobdeh F, ben Kraiem A, Attwood MM, Chubarev VN, Tarasov V V., Schiöth HB, et al. Pharmacological treatment of migraine: Drug classes, mechanisms of action, clinical trials and new treatments. Br J Pharmacol [Internet]. 2021 Dec 1 [cited 2023 Nov 23];178(23):4588–607. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/bph.15657
Rissardo JP, Caprara ALF. Gepants for Acute and Preventive Migraine Treatment: A Narrative Review. Brain Sci [Internet]. 2022 Dec 1 [cited 2023 Nov 23];12(12). Available from: /pmc/articles/PMC9775271/
Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S. Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev [Internet]. 2017 Apr 1 [cited 2023 Nov 23];97(2):553. Available from: /pmc/articles/PMC5539409/
Polderman TJC, Benyamin B, De Leeuw CA, Sullivan PF, Van Bochoven A, Visscher PM, et al. Meta-analysis of the heritability of human traits based on fifty years of twin studies. Nature Genetics 2015 47:7 [Internet]. 2015 May 18 [cited 2024 Jan 10];47(7):702–9. Available from: https://www.nature.com/articles/ng.3285
Gormley P, Anttila V, Winsvold BS, Palta P, Esko T, Pers TH, et al. Meta-analysis of 375,000 individuals identifies 38 susceptibility loci for migraine. Nature Genetics 2016 48:8 [Internet]. 2016 Jun 20 [cited 2024 Jan 10];48(8):856–66. Available from: https://www.nature.com/articles/ng.3598
Olesen J. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan 1;38(1):1–211.
Steiner TJ, Jensen R, Katsarava Z, Linde M, MacGregor EA, Osipova V, et al. Aids to management of headache disorders in primary care (2nd edition) : on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. J Headache Pain [Internet]. 2019 May 21 [cited 2024 Jan 10];20(1). Available from: https://pubmed.ncbi.nlm.nih.gov/31113373/
Singh A, Gupta D, Sahoo AK. Acute Migraine: Can the New Drugs Clinically Outpace? SN Comprehensive Clinical Medicine 2020 2:8 [Internet]. 2020 Jul 9 [cited 2023 Nov 23];2(8):1132–8. Available from: https://link.springer.com/article/10.1007/s42399-020-00390-1
Ogunlaja OI, Goadsby PJ. Headache: Treatment update. eNeurologicalSci [Internet]. 2022 Dec 1 [cited 2023 Nov 23];29:100420. Available from: /pmc/articles/PMC9830470/
Leczenie farmakologiczne migreny. Podsumowanie aktualnych wytycznych European Federation of Neurological Societies - Migrena - Migrena i bóle głowy - Choroby - Neurologia - Medycyna Praktyczna dla lekarzy [Internet]. [cited 2023 Nov 24]. Available from: https://www.mp.pl/neurologia/choroby/bole-glowy/migrena/52321,leczenie-farmakologiczne-migreny-podsumowanie-aktualnych-wytycznych-european-federation-of-neurological-societies
Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology [Internet]. 2008 Nov 25 [cited 2024 Jan 10];71(22):1821–8. Available from: https://pubmed.ncbi.nlm.nih.gov/19029522/
Schwedt TJ, Hentz JG, Sahai-Srivastava S, Spare NM, Martin VT, Treppendahl C, et al. Headache characteristics and burden from chronic migraine with medication overuse headache: Cross-sectional observations from the Medication Overuse Treatment Strategy trial. Headache [Internet]. 2021 Feb 1 [cited 2024 Jan 10];61(2):351–62. Available from: https://pubmed.ncbi.nlm.nih.gov/33432635/
Dodick DW, Lipton RB, Goadsby PJ, Tfelt-Hansen P, Ferrari MD, Diener HC, et al. Predictors of migraine headache recurrence: a pooled analysis from the eletriptan database. Headache [Internet]. 2008 Feb [cited 2024 Jan 10];48(2):184–93. Available from: https://pubmed.ncbi.nlm.nih.gov/18234045/
Puledda F, Tassorelli C, Diener HC. New migraine drugs. https://doi.org/101177/03331024221144784 [Internet]. 2023 Feb 14 [cited 2023 Nov 24];43(3). Available from: https://journals.sagepub.com/doi/full/10.1177/03331024221144784?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org
Karsan N, Goadsby PJ. New Oral Drugs for Migraine. CNS Drugs [Internet]. 2022 Sep 1 [cited 2023 Nov 27];36(9):933. Available from: /pmc/articles/PMC9477894/
Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain [Internet]. 2019 Jul 1 [cited 2023 Nov 28];142(7):1894. Available from: /pmc/articles/PMC6620826/
Lipton RB, Dodick DW, Ailani J, Lu K, Finnegan M, Szegedi A, et al. Effect of Ubrogepant vs Placebo on Pain and the Most Bothersome Associated Symptom in the Acute Treatment of Migraine: The ACHIEVE II Randomized Clinical Trial. JAMA [Internet]. 2019 Nov 11 [cited 2023 Nov 30];322(19):1887. Available from: /pmc/articles/PMC6865323/
Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, et al. Ubrogepant for the Treatment of Migraine. New England Journal of Medicine [Internet]. 2019 Dec 5 [cited 2023 Nov 30];381(23):2230–41. Available from: https://www.nejm.org/doi/10.1056/NEJMoa1813049
Moreno-Ajona D, Villar-Martínez MD, Goadsby PJ. New Generation Gepants: Migraine Acute and Preventive Medications. J Clin Med [Internet]. 2022 Mar 1 [cited 2023 Nov 30];11(6). Available from: /pmc/articles/PMC8953732/
Curto M, Capi M, Cipolla F, Cisale GY, Martelletti P, Lionetto L. Ubrogepant for the treatment of migraine. Expert Opin Pharmacother [Internet]. 2020 May 2 [cited 2023 Nov 30];21(7):755–9. Available from: https://www.tandfonline.com/doi/abs/10.1080/14656566.2020.1721462
Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. The Lancet. 2019 Aug 31;394(10200):737–45.
Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, et al. Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine. New England Journal of Medicine [Internet]. 2019 Jul 11 [cited 2023 Dec 1];381(2):142–9. Available from: https://www.nejm.org/doi/10.1056/NEJMoa1811090
Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. The Lancet. 2021 Jan 2;397(10268):51–60.
Ailani J, Burch RC, Robbins MS. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache: The Journal of Head and Face Pain [Internet]. 2021 Jul 1 [cited 2023 Dec 1];61(7):1021–39. Available from: https://onlinelibrary.wiley.com/doi/full/10.1111/head.14153
Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol. 2020 Sep 1;19(9):727–37.
Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L, et al. Atogepant for the Preventive Treatment of Migraine. New England Journal of Medicine [Internet]. 2021 Aug 19 [cited 2023 Dec 2];385(8):695–706. Available from: https://www.nejm.org/doi/10.1056/NEJMoa2035908
Croop R, Madonia J, Conway C, Thiry A, Forshaw M, Murphy A, et al. Intranasal Zavegepant is Effective and Well Tolerated for the Acute Treatment of Migraine: A Phase 2/3 Dose-Ranging Clinical trial (4976). Neurology. 2021;96(15 Supplement).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Aleksandra Kłos, Mateusz Pawlicki, Karol Stachyrak, Dawid Mika, Bartosz Mazur, Kamila Turek, Maciej Lambach, Anna Greguła, Aleksnadra Mazurek, Wiktoria Wilanowska
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 414
Number of citations: 0
